Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EPS (Weighted Average and Diluted) (2020 - 2026)

Ovid Therapeutics filings provide 7 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.12 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) rose 99.91% to -$0.12 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $206.0 through Mar 2026, up 152.79% year-over-year, with the annual reading at -$0.23 for FY2025, 99.94% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.12 in Q1 2026 for Ovid Therapeutics, down from $374.07 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $374.07 in Q4 2025 and bottomed at -$366.09 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$10.94, with a median of -$0.18 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 65438.89% in 2024, while the deepest fall reached 174228.57% in 2024.
  • Ovid Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.16 in 2022, then plummeted by 31.25% to -$0.21 in 2023, then plummeted by 174228.57% to -$366.09 in 2024, then surged by 202.18% to $374.07 in 2025, then crashed by 100.03% to -$0.12 in 2026.
  • Per Business Quant, the three most recent readings for OVID's EPS (Weighted Average and Diluted) are -$0.12 (Q1 2026), $374.07 (Q4 2025), and -$168.01 (Q3 2025).